Brief: Castle Biosciences Presents New Data Demonstrating The Impact Of Decisiondx®-Scc Test Results On The Management Of Medicare-Eligible Patients With Cutaneous Squamous Cell Carcinoma And One Or More Risk Factors
24/10/2022 13:49
Oct 24 (Reuters) - Castle Biosciences Inc CSTL.O :
* CASTLE BIOSCIENCES PRESENTS NEW DATA DEMONSTRATING THE
IMPACT OF
DECISIONDX®-SCC TEST RESULTS ON THE MANAGEMENT OF
MEDICARE-ELIGIBLE PATIENTS WITH CUTANEOUS SQUAMOUS CELL
CARCINOMA AND ONE OR MORE RISK FACTORS
Source text for Eikon: ID:nBw12dksba
Further company coverage: CSTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million